@article{oai:kanazawa-u.repo.nii.ac.jp:00013167,
 author = {Mabuchi, Hiroshi and Haba, Toshihiro and Tatami, Ryozo and Miyamoto, Susumu and Sakai, Yasuyuki and Wakasugi, Takanobu and Watanabe, Akira and Koizumi, Junji and Takeda, Ryoyu},
 issue = {9},
 journal = {New England Journal of Medicine},
 month = {Jan},
 note = {We studied the effects of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (KMG-CoA) reductase, on serum levels of lipoproteins and ubiquinone-10 in seven heterozygous patients with familial hypercholesterolemia. ML-236B was given at doses of 30 to 60 mg per day for 24 weeks. Serum cholesterol decreased from 390 ± 9 to 303 ± 8 mg per deciliter (10.1 ± 0.2 to 7.88 ± 0.2 mmol per liter, mean ± S.E.M.; P<0.001), and serum triglyceride decreased from 137 ± 18 to 87 ± 9 mg per deciliter (1.55 ± 0.20 to 0.98 ± 0.1 mmol per liter; P<0.05). Intermediate-density-lipoprotein (IDL) cholesterol, IDL triglyceride, low-density-lipoprotein (LDL) cholesterol, and LDL triglyceride decreased significantly (P<0.01, P<0.02, P<0.001, and P<0.001, respectively). However, there were no significant changes in very-low-density-lipoprotein (VLDL) cholesterol and triglyceride or high-density-lipoprotein (HDL) cholesterol. Serum ubiquinone-10 levels did not change, and LDL levels of ubiquinone-10 decreased by 50 per cent, from 0.39 ± 0.07 to 0.20 ± 0.01 μg per milliliter (P<0.05). No adverse effects were observed. We conclude that ML-236B is effective in lowering serum cholesterol without lowering serum ubiquinone-10 in heterozygous patients with familial hypercholesterolemia.},
 pages = {478--482},
 title = {Effects of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase on serum lipoproteins and ubiquinone-10 levels in patients with familial hypercholesterolemia},
 volume = {305},
 year = {1981}
}